{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T21:19:54Z","timestamp":1794431994426,"version":"4.9.1"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"vor","delay-in-days":85,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"MEXT | Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["22K19368"],"award-info":[{"award-number":["22K19368"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"MEXT | Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["25K22515"],"award-info":[{"award-number":["25K22515"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007434","name":"Suzuken Memorial Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007434","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019356","name":"SGH Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100019356","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Biol"],"DOI":"10.1038\/s42003-026-10374-x","type":"journal-article","created":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T10:45:31Z","timestamp":1779792331000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Dual targeting of glutamine metabolism and lysosomal function in eliminating drug-tolerant KRAS-mutant cancer cells"],"prefix":"10.1038","volume":"9","author":[{"given":"Hiroki","family":"Furukawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2380-4453","authenticated-orcid":false,"given":"Keitaro","family":"Umezawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuchen","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hinata","family":"Chiba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marin","family":"Kubonishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayato","family":"Naito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuri","family":"Miura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kousei","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2821-0651","authenticated-orcid":false,"given":"Shigeki","family":"Aoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,26]]},"reference":[{"key":"10374_CR1","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646\u2013674 (2011).","journal-title":"Cell"},{"key":"10374_CR2","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1038\/nature03095","volume":"432","author":"C Sawyers","year":"2004","unstructured":"Sawyers, C. Targeted cancer therapy. Nature 432, 294\u2013297 (2004).","journal-title":"Nature"},{"key":"10374_CR3","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/nrc.2016.126","volume":"17","author":"R Dienstmann","year":"2017","unstructured":"Dienstmann, R. et al. Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer. Nat. Rev. Cancer 17, 79\u201392 (2017).","journal-title":"Nat. Rev. Cancer"},{"key":"10374_CR4","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1158\/2159-8290.CD-12-0012","volume":"2","author":"LA Garraway","year":"2012","unstructured":"Garraway, L. A. & J\u00e4nne, P. A. Circumventing cancer drug resistance in the era of personalized medicine. Cancer Discov. 2, 214\u2013226 (2012).","journal-title":"Cancer Discov."},{"key":"10374_CR5","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","volume":"364","author":"PB Chapman","year":"2011","unstructured":"Chapman, P. B. et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation.  N. Engl. J. Med. 364, 2507\u20132516 (2011).","journal-title":"N. Engl. J. Med."},{"key":"10374_CR6","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1126\/science.1099314","volume":"304","author":"JG Paez","year":"2004","unstructured":"Paez, J. G. et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304, 1497\u20131500 (2004).","journal-title":"Science"},{"key":"10374_CR7","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/nm.2697","volume":"18","author":"W Pao","year":"2012","unstructured":"Pao, W. & Hutchinson, K. E. Chipping away at the lung cancer genome. Nat. Med. 18, 349\u2013351 (2012).","journal-title":"Nat. Med."},{"key":"10374_CR8","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nature05945","volume":"448","author":"M Soda","year":"2007","unstructured":"Soda, M. et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448, 561\u2013566 (2007).","journal-title":"Nature"},{"key":"10374_CR9","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/nature11412","volume":"490","author":"Cancer Genome Atlas Network","year":"2012","unstructured":"Cancer Genome Atlas Network Comprehensive molecular portraits of human breast tumours. Nature 490, 61\u201370 (2012).","journal-title":"Nature"},{"key":"10374_CR10","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.cell.2013.03.002","volume":"153","author":"LA Garraway","year":"2013","unstructured":"Garraway, L. A. & Lander, E. S. Lessons from the cancer genome. Cell 153, 17\u201337 (2013).","journal-title":"Cell"},{"key":"10374_CR11","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1038\/nrc3599","volume":"13","author":"C Holohan","year":"2013","unstructured":"Holohan, C., Van Schaeybroeck, S., Longley, D. B. & Johnston, P. G. Cancer drug resistance: an evolving paradigm. Nat. Rev. Cancer 13, 714\u2013726 (2013).","journal-title":"Nat. Rev. Cancer"},{"key":"10374_CR12","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/nm.4040","volume":"22","author":"AN Hata","year":"2016","unstructured":"Hata, A. N. et al. Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition. Nat. Med. 22, 262\u2013269 (2016).","journal-title":"Nat. Med."},{"key":"10374_CR13","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/nature24297","volume":"551","author":"MJ Hangauer","year":"2017","unstructured":"Hangauer, M. J. et al. Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition. Nature 551, 247\u2013250 (2017).","journal-title":"Nature"},{"key":"10374_CR14","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.cell.2010.02.027","volume":"141","author":"SV Sharma","year":"2010","unstructured":"Sharma, S. V. et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 141, 69\u201380 (2010).","journal-title":"Cell"},{"key":"10374_CR15","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1038\/s41586-021-03796-6","volume":"596","author":"Y Oren","year":"2021","unstructured":"Oren, Y. et al. Cycling cancer persister cells arise from lineages with distinct programs. Nature 596, 576\u2013582 (2021).","journal-title":"Nature"},{"key":"10374_CR16","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1038\/nrd4389","volume":"13","author":"AD Cox","year":"2014","unstructured":"Cox, A. D., Fesik, S. W., Kimmelman, A. C., Luo, J. & Der, C. J. Drugging the undruggable RAS: mission possible? Nat. Rev. Drug Discov. 13, 828\u2013851 (2014).","journal-title":"Nat. Rev. Drug Discov."},{"key":"10374_CR17","doi-asserted-by":"publisher","first-page":"2969","DOI":"10.1158\/0008-5472.CAN-19-3682","volume":"80","author":"IA Prior","year":"2020","unstructured":"Prior, I. A., Hood, F. E. & Hartley, J. L. The frequency of ras mutations in cancer. Cancer Res. 80, 2969\u20132974 (2020).","journal-title":"Cancer Res."},{"key":"10374_CR18","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/s41586-019-1694-1","volume":"575","author":"J Canon","year":"2019","unstructured":"Canon, J. et al. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature 575, 217\u2013223 (2019).","journal-title":"Nature"},{"key":"10374_CR19","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1056\/NEJMoa2204619","volume":"387","author":"PA J\u00e4nne","year":"2022","unstructured":"J\u00e4nne, P. A. et al. Adagrasib in non-small-cell lung cancer harboring a KRAS(G12C) mutation.  N. Engl. J. Med. 387, 120\u2013131 (2022).","journal-title":"N. Engl. J. Med."},{"key":"10374_CR20","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1056\/NEJMoa2103695","volume":"384","author":"F Skoulidis","year":"2021","unstructured":"Skoulidis, F. et al. Sotorasib for lung cancers with KRAS p.G12C Mutation.  N. Engl. J. Med. 384, 2371\u20132381 (2021).","journal-title":"N. Engl. J. Med."},{"key":"10374_CR21","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1056\/NEJMoa2105281","volume":"384","author":"MM Awad","year":"2021","unstructured":"Awad, M. M. et al. Acquired resistance to KRAS(G12C) inhibition in cancer.  N. Engl. J. Med. 384, 2382\u20132393 (2021).","journal-title":"N. Engl. J. Med."},{"key":"10374_CR22","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1158\/1078-0432.CCR-19-3523","volume":"26","author":"MB Ryan","year":"2020","unstructured":"Ryan, M. B. et al. Vertical pathway inhibition overcomes adaptive feedback resistance to KRAS(G12C) inhibition. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 26, 1633\u20131643 (2020).","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"10374_CR23","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/s41586-019-1884-x","volume":"577","author":"JY Xue","year":"2020","unstructured":"Xue, J. Y. et al. Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition. Nature 577, 421\u2013425 (2020).","journal-title":"Nature"},{"key":"10374_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms10690","volume":"7","author":"M Ramirez","year":"2016","unstructured":"Ramirez, M. et al. Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells. Nat. Commun. 7, 10690 (2016).","journal-title":"Nat. Commun."},{"key":"10374_CR25","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/nature22794","volume":"546","author":"SM Shaffer","year":"2017","unstructured":"Shaffer, S. M. et al. Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance. Nature 546, 431\u2013435 (2017).","journal-title":"Nature"},{"key":"10374_CR26","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nature23007","volume":"547","author":"VS Viswanathan","year":"2017","unstructured":"Viswanathan, V. S. et al. Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway. Nature 547, 453\u2013457 (2017).","journal-title":"Nature"},{"key":"10374_CR27","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1158\/2159-8290.CD-19-1167","volume":"10","author":"J Hallin","year":"2020","unstructured":"Hallin, J. et al. The KRASG12C inhibitor MRTX849 provides insight toward therapeutic susceptibility of KRAS-mutant cancers in mouse models and patients. Cancer Discov. 10, 54\u201371 (2020).","journal-title":"Cancer Discov."},{"key":"10374_CR28","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.freeradbiomed.2006.02.012","volume":"41","author":"NI Fedotcheva","year":"2006","unstructured":"Fedotcheva, N. I., Sokolov, A. P. & Kondrashova, M. N. Nonezymatic formation of succinate in mitochondria under oxidative stress. Free Radic. Biol. Med. 41, 56\u201364 (2006).","journal-title":"Free Radic. Biol. Med."},{"key":"10374_CR29","doi-asserted-by":"publisher","first-page":"8972","DOI":"10.1523\/JNEUROSCI.20-24-08972.2000","volume":"20","author":"L Tretter","year":"2000","unstructured":"Tretter, L. & Adam-Vizi, V. Inhibition of Krebs cycle enzymes by hydrogen peroxide: A key role of [alpha]-ketoglutarate dehydrogenase in limiting NADH production under oxidative stress.  J. Neurosci. Off. J. Soc. Neurosci. 20, 8972\u20138979 (2000).","journal-title":"J. Neurosci. Off. J. Soc. Neurosci."},{"key":"10374_CR30","doi-asserted-by":"publisher","first-page":"3123","DOI":"10.1021\/acs.jmedchem.1c01688","volume":"65","author":"X Wang","year":"2022","unstructured":"Wang, X. et al. Identification of MRTX1133, a noncovalent, potent, and selective KRAS(G12D) inhibitor. J. Med. Chem. 65, 3123\u20133133 (2022).","journal-title":"J. Med. Chem."},{"key":"10374_CR31","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1126\/science.1254721","volume":"346","author":"AS Crystal","year":"2014","unstructured":"Crystal, A. S. et al. Patient-derived models of acquired resistance can identify effective drug combinations for cancer. Science 346, 1480\u20131486 (2014).","journal-title":"Science"},{"key":"10374_CR32","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1038\/nrm2233","volume":"8","author":"J Campisi","year":"2007","unstructured":"Campisi, J. & d\u2019Adda di Fagagna, F. Cellular senescence: when bad things happen to good cells. Nat. Rev. Mol. cell Biol. 8, 729\u2013740 (2007).","journal-title":"Nat. Rev. Mol. cell Biol."},{"key":"10374_CR33","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.tcb.2018.02.001","volume":"28","author":"A Hernandez-Segura","year":"2018","unstructured":"Hernandez-Segura, A., Nehme, J. & Demaria, M. Hallmarks of cellular senescence. Trends cell Biol. 28, 436\u2013453 (2018).","journal-title":"Trends cell Biol."},{"key":"10374_CR34","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1038\/s41586-025-08917-z","volume":"642","author":"C Cheng","year":"2025","unstructured":"Cheng, C. et al. Targeting PIKfyve-driven lipid metabolism in pancreatic cancer. Nature 642, 776\u2013784 (2025).","journal-title":"Nature"},{"key":"10374_CR35","doi-asserted-by":"publisher","first-page":"2198","DOI":"10.1158\/2159-8290.CD-22-0044","volume":"12","author":"M Ravichandran","year":"2022","unstructured":"Ravichandran, M. et al. Coordinated transcriptional and catabolic programs support iron-dependent adaptation to RAS-MAPK pathway inhibition in pancreatic cancer. Cancer Discov. 12, 2198\u20132219 (2022).","journal-title":"Cancer Discov."},{"key":"10374_CR36","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1083\/jcb.201511036","volume":"212","author":"P Mishra","year":"2016","unstructured":"Mishra, P. & Chan, D. C. Metabolic regulation of mitochondrial dynamics.  J. cell Biol. 212, 379\u2013387 (2016).","journal-title":"J. cell Biol."},{"key":"10374_CR37","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1126\/science.1219855","volume":"337","author":"RJ Youle","year":"2012","unstructured":"Youle, R. J. & van der Bliek, A. M. Mitochondrial fission, fusion, and stress. Science 337, 1062\u20131065 (2012).","journal-title":"Science"},{"key":"10374_CR38","doi-asserted-by":"publisher","first-page":"e1600200","DOI":"10.1126\/sciadv.1600200","volume":"2","author":"RJ DeBerardinis","year":"2016","unstructured":"DeBerardinis, R. J. & Chandel, N. S. Fundamentals of cancer metabolism. Sci. Adv. 2, e1600200 (2016).","journal-title":"Sci. Adv."},{"key":"10374_CR39","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1038\/nature10642","volume":"481","author":"AR Mullen","year":"2011","unstructured":"Mullen, A. R. et al. Reductive carboxylation supports growth in tumour cells with defective mitochondria. Nature 481, 385\u2013388 (2011).","journal-title":"Nature"},{"key":"10374_CR40","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.cmet.2015.12.006","volume":"23","author":"NN Pavlova","year":"2016","unstructured":"Pavlova, N. N. & Thompson, C. B. The emerging hallmarks of cancer metabolism. Cell Metab. 23, 27\u201347 (2016).","journal-title":"Cell Metab."},{"key":"10374_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/srep30767","volume":"6","author":"SM Jeong","year":"2016","unstructured":"Jeong, S. M., Hwang, S., Park, K., Yang, S. & Seong, R. H. Enhanced mitochondrial glutamine anaplerosis suppresses pancreatic cancer growth through autophagy inhibition. Sci. Rep. 6, 30767 (2016).","journal-title":"Sci. Rep."},{"key":"10374_CR42","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1042\/EBC20190041","volume":"64","author":"A Judge","year":"2020","unstructured":"Judge, A. & Dodd, M. S. Metabolism. Essays Biochem. 64, 607\u2013647 (2020).","journal-title":"Essays Biochem."},{"key":"10374_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/srep37594","volume":"6","author":"JW Seo","year":"2016","unstructured":"Seo, J. W. et al. Autophagy is required for PDAC glutamine metabolism. Sci. Rep. 6, 37594 (2016).","journal-title":"Sci. Rep."},{"key":"10374_CR44","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/nature12040","volume":"496","author":"J Son","year":"2013","unstructured":"Son, J. et al. Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. Nature 496, 101\u2013105 (2013).","journal-title":"Nature"},{"key":"10374_CR45","doi-asserted-by":"publisher","first-page":"3502","DOI":"10.1016\/j.molcel.2023.08.032","volume":"83","author":"L He","year":"2023","unstructured":"He, L. et al. Lysosomal cyst(e)ine storage potentiates tolerance to oxidative stress in cancer cells. Mol. Cell 83, 3502\u20133519.e3511 (2023).","journal-title":"Mol. Cell"},{"key":"10374_CR46","doi-asserted-by":"publisher","first-page":"238","DOI":"10.3389\/fnins.2019.00238","volume":"13","author":"M Quiles Del Rey","year":"2019","unstructured":"Quiles Del Rey, M. & Mancias, J. D. NCOA4-mediated ferritinophagy: a potential link to neurodegeneration. Front. Neurosci. 13, 238 (2019).","journal-title":"Front. Neurosci."},{"key":"10374_CR47","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1038\/s41392-023-01503-7","volume":"8","author":"S Wang","year":"2023","unstructured":"Wang, S. et al. The mitophagy pathway and its implications in human diseases. Signal Transduct. Target. Ther. 8, 304 (2023).","journal-title":"Signal Transduct. Target. Ther."},{"key":"10374_CR48","doi-asserted-by":"publisher","first-page":"115121","DOI":"10.1016\/j.biopha.2023.115121","volume":"165","author":"X He","year":"2023","unstructured":"He, X. et al. The role of redox-mediated lysosomal dysfunction and therapeutic strategies. Biomed. Pharmacother. 165, 115121 (2023).","journal-title":"Biomed. Pharmacother."},{"key":"10374_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-13668-3","volume":"11","author":"I Mart\u00ednez-Reyes","year":"2020","unstructured":"Mart\u00ednez-Reyes, I. & Chandel, N. S. Mitochondrial TCA cycle metabolites control physiology and disease. Nat. Commun. 11, 102 (2020).","journal-title":"Nat. Commun."},{"key":"10374_CR50","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/j.cell.2017.04.004","volume":"169","author":"MD Buck","year":"2017","unstructured":"Buck, M. D., Sowell, R. T., Kaech, S. M. & Pearce, E. L. Metabolic Instruction of Immunity. Cell 169, 570\u2013586 (2017).","journal-title":"Cell"},{"key":"10374_CR51","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1038\/s41568-020-0273-y","volume":"20","author":"RD Leone","year":"2020","unstructured":"Leone, R. D. & Powell, J. D. Metabolism of immune cells in cancer. Nat. Rev. Cancer 20, 516\u2013531 (2020).","journal-title":"Nat. Rev. Cancer"},{"key":"10374_CR52","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1158\/2159-8290.CD-19-0292","volume":"9","author":"RK Amaravadi","year":"2019","unstructured":"Amaravadi, R. K., Kimmelman, A. C. & Debnath, J. Targeting autophagy in cancer: recent advances and future directions. Cancer Discov. 9, 1167\u20131181 (2019).","journal-title":"Cancer Discov."},{"key":"10374_CR53","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1158\/1535-7163.MCT-13-0870","volume":"13","author":"MI Gross","year":"2014","unstructured":"Gross, M. I. et al. Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer. Mol. Cancer Therapeutics 13, 890\u2013901 (2014).","journal-title":"Mol. Cancer Therapeutics"},{"key":"10374_CR54","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1126\/science.aav2588","volume":"366","author":"RD Leone","year":"2019","unstructured":"Leone, R. D. et al. Glutamine blockade induces divergent metabolic programs to overcome tumor immune evasion. Science 366, 1013\u20131021 (2019).","journal-title":"Science"},{"key":"10374_CR55","first-page":"778","volume":"24","author":"Y Sun","year":"2019","unstructured":"Sun, Y., Saito, K., Iiji, R. & Saito, Y. Application of ion chromatography coupled with mass spectrometry for human serum and urine metabolomics. SLAS Discov. Advancing Life Sci. R. D. 24, 778\u2013786 (2019).","journal-title":"SLAS Discov. Advancing Life Sci. R. D."}],"container-title":["Communications Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s42003-026-10374-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-026-10374-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-026-10374-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T22:33:25Z","timestamp":1787092405000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s42003-026-10374-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,26]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["10374"],"URL":"https:\/\/doi.org\/10.1038\/s42003-026-10374-x","relation":{},"ISSN":["2399-3642"],"issn-type":[{"value":"2399-3642","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,26]]},"assertion":[{"value":"3 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"1117"}}